Cargando…
Functional differences between PD-1(+) and PD-1(-) CD4(+) effector T cells in healthy donors and patients with glioblastoma multiforme
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been highly successful in the treatment of cancer. While PD-1 expression has been widely investigated, its role in CD4(+) effector T cells in the setting of health and cancer remains unclear, particularly in the setti...
Autores principales: | Goods, Brittany A., Hernandez, Amanda L., Lowther, Daniel E., Lucca, Liliana E., Lerner, Benjamin A., Gunel, Murat, Raddassi, Khadir, Coric, Vlad, Hafler, David A., Love, J. Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589094/ https://www.ncbi.nlm.nih.gov/pubmed/28880903 http://dx.doi.org/10.1371/journal.pone.0181538 |
Ejemplares similares
-
PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019) -
Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
por: Lucca, Liliana E., et al.
Publicado: (2020) -
Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
por: Heiland, Dieter Henrik, et al.
Publicado: (2017) -
CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome
por: Choileáin, Siobhán Ní, et al.
Publicado: (2019) -
PD-L1 – PD-1 interactions limit effector regulatory T cell
populations at homeostasis and during infection
por: Perry, Joseph A., et al.
Publicado: (2022)